Floatz logo

Neratinib

Breast Neoplasms

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversitySmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
65/ 100

Competitive context

176 Active assets in the Breast Neoplasms cohort.

Asset / SponsorPhaseRating
Docetaxel
Universitas Airlangga
Phase 4BB
Inno-206
Merck Sharp & Dohme LLC
Phase 4BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 4BB
EXEMESTANE
Fujian Cancer Hospital
Phase 4BB
TAMOXIFEN
Eli Lilly and Company
Phase 3BB

View all 50 →

Same molecule, other indications

Neratinib is also rated in:

breast carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Metastatic Breast CarcinomaDormant
B
Indicative ·
62 / 100
View asset →
breast cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →